ArticleOncotarget2016
Combination of tolfenamic acid and curcumin induces colon cancer cell growth inhibition through modulating specific transcription factors and reactive oxygen species.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 58 citations in OpenAlex.
- Low, plasma level‑informed native curcumin concentrations fail to induce cell death in human lung and colorectal cancer cells.Pharmaceutical biology · 2026Article
- Article
- Multi-target Mechanisms of Natural Compounds in Inhibiting Colitis-Associated Carcinogenesis: Implications for Novel Therapeutic Strategies.Chinese journal of integrative medicine · 2026Review
- A nano drug delivery system loading drugs and chlorin e6 separately to achieve photodynamic-chemo combination therapy.Nanomedicine (London, England) · 2025Article
- Exploring the oncogenic roles of T-box transcription factor TBX2 and its potential as a therapeutic target.Biochemical Society transactions · 2025Review
- Prominent Naturally Derived Oxidative-Stress-Targeting Drugs and Their Applications in Cancer Treatment.Antioxidants (Basel, Switzerland) · 2025Review
- Self-assembly nanoplatform of platinum (Ⅳ) prodrug for enhanced ovarian cancer therapy.Materials today. Bio · 2023Article
- Therapeutic Applications of Curcumin and Derivatives in Colorectal Cancer.Onco therapeutics · 2022Article
- Updated Review on the Role of Curcumin in Gastrointestinal Cancers.Advances in experimental medicine and biology · 2021Review
- Antimetastatic Effects of Curcumin in Oral and Gastrointestinal Cancers.Frontiers in pharmacology · 2021Review
- Free Radicals as a Double-Edged Sword: The Cancer Preventive and Therapeutic Roles of Curcumin.Molecules (Basel, Switzerland) · 2020Review
- Epigenetics/epigenomics and prevention by curcumin of early stages of inflammatory-driven colon cancer.Molecular carcinogenesis · 2020Review
- Synthesis and discovery of asiatic acid based 1,2,3-triazole derivatives as antitumor agents blocking NF-κB activation and cell migration.MedChemComm · 2019Article
- Clotam enhances anti-proliferative effect of vincristine in Ewing sarcoma cells.Apoptosis : an international journal on programmed cell death · 2019Article
- Powerful anti-colon cancer effect of modified nanoparticle-mediated IL-15 immunogene therapy through activation of the host immune system.Theranostics · 2018Article
- Shenqi Fuzheng Injection Reverses Cisplatin Resistance through Mitofusin-2-Mediated Cell Cycle Arrest and Apoptosis in A549/DDP Cells.Evidence-based complementary and alternative medicine : eCAM · 2018Article
- In vitro additive antitumor effects of dimethoxycurcumin and 5-fluorouracil in colon cancer cells.Cancer medicine · 2017Article
- Article
- Furanodienone induces G0/G1 arrest and causes apoptosis via the ROS/MAPKs-mediated caspase-dependent pathway in human colorectal cancer cells: a study in vitro and in vivo.Cell death & disease · 2017Article
- MicroRNA-7 functions as a tumor-suppressor gene by regulating ILF2 in pancreatic carcinoma.International journal of molecular medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Curcumin (Cur) has been extensively studied in several types of malignancies including colorectal cancer (CRC); however its clinical application is greatly affected by low bioavailability. Several strategies to improve the therapeutic response of Cur are being pursued, including its combination with small molecules and drugs. We investigated the therapeutic efficacy of Cur in combination with the small molecule tolfenamic acid (TA) in CRC cell lines. TA has been shown to inhibit the growth of human cancer cells in vitro and in vivo, via targeting the transcription factor specificity protein1 (Sp1) and suppressing survivin expression. CRC cell lines HCT116 and HT29 were treated with TA and/or Cur and cell viability was measured 24-72 hours post-treatment. While both agents caused a steady reduction in cell viability, following a clear dose/ time-dependent response, the combination of TA+Cur showed higher growth inhibition when compared to either single agent. Effects on apoptosis were determined using flow cytometry (JC-1 staining to measure mitochondrial membrane potential), Western blot analysis (c-PARP expression) and caspase 3/7 activity. Reactive oxygen species (ROS) levels were measured by flow cytometry and the translocation of NF-kB into the nucleus was determined using immunofluorescence. Results showed that apoptotic markers and ROS activity were significantly upregulated following combination treatment, when compared to the individual agents. This was accompanied by decreased expression of Sp1, survivin and NF-kB translocation. The combination of TA+Cur was more effective in HCT116 cells than HT29 cells. These results demonstrate that TA may enhance the anti-proliferative efficacy of Cur in CRC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.